Antipsychotic polypharmacy in children and adolescents at discharge from psychiatric hospitalization

Pharmacotherapy

Volumn 34, Issue 8, 2014, Pages 836-844

  Saldaña, Shannon N ^a,b   Keeshin, Brooks R ^c   Wehry, Anna M ^d   Blom, Thomas J ^d   Sorter, Michael T ^b   Delbello, Melissa P ^b,d   Strawn, Jeffrey R ^b,d  

^a PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

antipsychotic; child and adolescent psychiatry; polypharmacy; psychiatric hospitalization

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE;

ADOLESCENT; AGGRESSION; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CHILD HOSPITALIZATION; DEPRESSION; DEVELOPMENTAL DISORDER; DISRUPTIVE BEHAVIOR; EATING DISORDER; FAMILY; FEMALE; HUMAN; IMPULSIVENESS; INTELLECTUAL IMPAIRMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MENTAL HOSPITAL; MONOTHERAPY; MOOD DISORDER; POLYPHARMACY; PRESCRIPTION; PSYCHOSIS; RETROSPECTIVE STUDY; SUICIDAL IDEATION; SUICIDE ATTEMPT; VIOLENCE; CLINICAL PRACTICE; HOSPITAL; HOSPITAL DISCHARGE; HOSPITALIZATION; MENTAL DISORDERS; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; FEMALE; HOSPITALIZATION; HOSPITALS, PEDIATRIC; HUMANS; MALE; MENTAL DISORDERS; PATIENT DISCHARGE; PHYSICIAN'S PRACTICE PATTERNS; POLYPHARMACY; RETROSPECTIVE STUDIES;

EID: 84906101688     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1453     Document Type: Article

References (58)

1. Blader JC,. Acute inpatient care for psychiatric disorders in the United States, 1996 through 2007. Arch Gen Psychiatry 2011; 68: 1276-83.
2. Olfson M, Blanco C, Liu SM, et al. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry 2012; 69: 1247-56.
3. Olfson M, Crystal S, Huang C, et al. Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry 2010; 49: 13-23.
4. Patel NC, Crismon ML, Hoagwood K, et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 2005; 44: 548-56.
5. Crystal S, Olfson M, Huang C, et al. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood) 2009; 28: w770-81.
6. Olfson M, Blanco C, Liu L, et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006; 63: 679-85.
7. Matone M, Localio R, Huang YS, et al. The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of U.S. Medicaid-enrolled children. Health Serv Res 2012; 47: 1836-60.
8. Zito JM, Burcu M, Ibe A, et al. Antipsychotic use by Medicaid-insured youths: impact of eligibility and psychiatric diagnosis across a decade. Psychiatr Serv 2013; 64: 223-9.
9. Alessi-Severini S, Biscontri RG, Collins DM, et al. Ten years of antipsychotic prescribing to children: a Canadian population-based study. Can J Psychiatry 2012; 57: 52-8.
10. Rani F, Murray ML, Byrne PJ, et al. Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 2008; 121: 1002-9.
11. Comer JS, Olfson M, Mojtabai R,. National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. J Am Acad Child Adolesc Psychiatry 2010; 49: 1001-10.
12. Kowatch RA, Fristad M, Birmaher B, et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005; 44: 213-35.
13. Myers SM, Johnson CP,. Management of children with autism spectrum disorders. Pediatrics 2007; 120: 1162-82.
14. Pappadopulos E, Macintyre Ii JC, Crismon ML, et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. J Am Acad Child Adolesc Psychiatry 2003; 42: 145-61.
15. Young CM, Findling RL,. Pharmacologic treatment of adolescent and child schizophrenia. Expert Rev Neurother 2004; 4: 53-60.
16. Correll CU,. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 2008; 47: 9-20.
17. McConville BJ, Sorter MT,. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychiatry 2004; 65 (suppl 6): 20-9.
18. Newcomer JW,. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 (suppl 1): 1-93.
19. Correll CU,. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry 2007; 46: 687-700.
20. Correll CU, Carlson HE,. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006; 45: 771-91.
21. Laita P, Cifuentes A, Doll A, et al. Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. J Child Adolesc Psychopharmacol 2007; 17: 487-502.
22. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302: 1765-73.
23. Toteja N, Gallego JA, Saito E, et al. Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment. Int J Neuropsychopharmacol 2014; 17: 1095-1105.
24. Constantine RJ, Boaz T, Tandon R,. Antipsychotic polypharmacy in the treatment of children and adolescents in the fee-for-service component of a large state Medicaid program. Clin Ther 2010; 32: 949-59.
25. Dosreis S, Yoon Y, Rubin DM, et al. Antipsychotic treatment among youth in foster care. Pediatrics 2011; 128: e1459-66.
26. Gallego JA, Nielsen J, De Hert M, et al. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf 2012a; 11: 527-42.
27. Lochmann van Bennekom MW, Gijsman HJ, Zitman FG,. Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness. J Psychopharmacol 2013; 27: 327-36.
28. Hospital Based Inpatient Psychiatric Services. Specifications manual for joint commission national quality measures (v2010A). Available from https://manual.jointcommission.org/pub/Manual/TableOfContentsTJC/ HBIPS-Brief-v2010A.pdf. Accessed June 24, 2014.
29. Hospital Based Inpatient Psychiatric Services. Specifications manual for joint commission national quality measures (v2013A1). Available from http://manual.jointcommission.org/releases/TJC2013A/MIF0120.html. Accessed June 24, 2014.
30. Correll CU, Gallego JA,. Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice. Psychiatr Clin North Am 2012; 35: 661-81.
31. Gallego JA, Bonetti J, Zhang J, et al. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 2012b; 138: 18-28.
32. Patel NC, Hariparsad M, Matias-Akthar M, et al. Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics. J Child Adolesc Psychopharmacol 2007; 17: 303-11.
33. Kelly DL, Love RC, MacKowick M, et al. Atypical antipsychotic use in a state hospital inpatient adolescent population. J Child Adolesc Psychopharmacol 2004; 14: 75-85.
34. Pappadopulos E, Jensen PS, Schur SB, et al. "Real world" atypical antipsychotic prescribing practices in public child and adolescent inpatient settings. Schizophr Bull 2002; 28: 111-21.
35. Connor DF, Fletcher KE, Wood JS,. Neuroleptic-related dyskinesias in children and adolescents. J Clin Psychiatry 2001; 62: 967-74.
36. Morrato EH, Dodd S, Oderda G, et al. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003. Clin Ther 2007; 29: 183-95.
37. Children's Mental Health. Concerns remain about appropriate services for children in Medicaid and foster care. Washington, D.C.: U.S. Government Accountability Office; 2012. Available from http://www.gao.gov/assets/660/ 650716.pdf. Accessed June 24, 2014.
38. Curtis LH, Masselink LE, Ostbye T, et al. Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States. Arch Pediatr Adolesc Med 2005; 159: 362-6.
39. Medicaid Medical Directors Learning Network/Rutgers CERT. Antipsychotic medication use in Medicaid children and adolescents: report and resource guide from a 16-state study. Rutgers, NJ: Medicaid Medication Directors Learning Network, Rutgers Center for Education and Research on Mental Health Therapeutics; 2010. Available from http://rci.rutgers.edu/~cseap/MMDLNAPKIDS/ Antipsychotic-Use-in-Medicaid-Children-Report-and-Resource-Guide-Final.pdf. Accessed June 24, 2014.
40. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed, text revised. Washington, DC: American Psychiatric Association; 2000.
41. Castro-Fornieles J, Parellada M, Soutullo CA, et al. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach. J Child Adolesc Psychopharmacol 2008; 18: 327-36.
42. Dean AJ, McDermott BM, Marshall RT,. Psychotropic medication utilization in a child and adolescent mental health service. J Child Adolesc Psychopharmacol 2006; 16: 273-85.
43. Hong IS, Bishop JR,. Anticholinergic use in children and adolescents after initiation of antipsychotic therapy. Ann Pharmacother 2010; 44: 1171-80.
44. Jerrell JM, McIntyre RS,. Adverse events in children and adolescents treated with antipsychotic medications. Hum Psychopharmacol 2008; 23: 283-90.
45. Kogut SJ, Yam F, Dufresne R,. Prescribing of antipsychotic medication in a Medicaid population: use of polytherapy and off-label dosages. J Manag Care Pharm 2005; 11: 17-24.
46. Simeon J, Milin R, Walker S,. A retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 267-75.
47. Wonodi I, Reeves G, Carmichael D, et al. Tardive dyskinesia in children treated with atypical antipsychotic medications. Mov Disord 2007; 22: 1777-82.
48. Kutz GD,. Testimony before U.S. Senate. Foster children: HHS guidance could help states improve oversight of psychotropic prescriptions. Washington, DC: U.S. Government Accountability Office; 2011. Available from http://gao.gov/assets/590/586570.pdf. Accessed June 24, 2014.
49. Pottick KJ, McAlpine DD, Andelman RB,. Changing patterns of psychiatric inpatient care for children and adolescents in general hospitals, 1988-1995. Am J Psychiatry 2000; 157: 1267-73.
50. Bodner E, Sarel A, Gillath O, et al. The relationship between type of insurance, time period and length of stay in psychiatric hospitals: the Israeli case. Isr J Psychiatry Relat Sci 2010; 47: 284-90.
51. Fombonne E,. Epidemiology of pervasive developmental disorders. Pediatr Res 2009; 65: 591-8.
52. Aman MG,. Assessing psychopathology and behavior problems in persons with mental retardation: a review of available instruments. Washington, DC: Department of Health & Human Services publication no. (ADM) 91-1712; 1991. Available from http://files.eric.ed.gov/fulltext/ED342801.pdf. Accessed June 24, 2014.
53. Benson BA,. Behavior disorders and mental retardation: associations with age, sex, and level of functioning in an outpatient clinic sample. Appl Res Ment Retard 1985; 6: 79-85.
54. Reiss S,. Prevalence of dual diagnosis in community-based day programs in the Chicago metropolitan area. Am J Ment Retard 1990; 94: 578-85.
55. Pringsheim T, Gorman D,. Second-generation antipsychotics for the treatment of disruptive behaviour disorders in children: a systematic review. Can J Psychiatry 2012; 57: 722-7.
56. Ruedrich SL, Swales TP, Rossvanes C, et al. Atypical antipsychotic medication improves aggression, but not self-injurious behaviour, in adults with intellectual disabilities. J Intellect Disabil Res 2008; 52 (Pt 2): 132-40.
57. Tyrer P, Oliver-Africano PC, Ahmed Z, et al. Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. Lancet 2008; 371: 57-63.
58. Rush AJ, Frances A, (Eds.). Guideline 4: medication treatment: general principles. Am J Ment Retard 2000; 105: 178-81.